Caris Q4 net income $82M; FY25 rev $812M (+97%); guides FY26 rev $1.0-1.02B

Caris Life Sciences, Inc.

2025-FY EPS reported -$3.22 revenue$812,033,000

Q4 2025 revenue $292.9M (+125% YoY); net income $82.0M vs loss of $36.9M prior year.
Full year 2025 revenue $812.0M (+97% YoY); net loss narrowed to $68.1M from $281.9M; Adj. EBITDA $137.7M.
Gross margin improved to 75% in Q4 (from 54%) and 66% for FY (from 43%).
FY26 revenue guidance $1.0-1.02B (23-26% growth); molecular profiling rev growth ~21-22%.
Interim readout of Achieve 1 study for Caris Detect MCED test completed; launch expected H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.